Professor of Surgery, Brigham and Women's Hospital
General Surgery
Dr. Monica M. Bertagnolli, MD
|
|
Give Review
Doctor Monica M. Bertagnolli, MD is an expert in the field of General Surgery. She went to University of Utah School of Medicine. She received awards:"Boston Magazine", "Meaningful Use Stage 1 Certification" and "Fellow (FACS)". Monica Bertagnolli is a published doctor and has 63 publications published. The lastest was: 'Comparison of Gastric Cancer Survival Between Caucasian and Asian Patients Treated in the United States: Results from the Surveillance Epidemiology and End Results (SE...'
Publications
- Celecoxib inhibits early cutaneous wound healing.
- Antitumor effects of hyaluronan inhibition in desmoid Tumors.
- Comparison of Gastric Cancer Survival Between Caucasian and Asian Patients Treated in the United States: Results from the Surveillance Epidemiology and End Results (SE...
- Expanding Public-Private Collaborations to Enhance Cancer Drug Development: A Report of the Institute of Medicine's Workshop Series, "Implementing a National Cancer Cl...
- CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer.
- Lack of anti-tumor activity with the β-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of Intestinal carcinogenesis.
- Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial.
- Germline Variants and Advanced ColoRectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study.
- Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance).
- Estrogen receptor α or β loss in the colon of Min/+ mice promotes crypt expansion and impairs TGFβ and HNF3β signaling.
- Association of TP53 Mutational Status and Gender with Survival After Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803.
- Predictors for major wound complications following preoperative radiotherapy and surgery for Soft-tissue sarcoma of the extremities and trunk: importance of tumor prox...
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581.
- Locoregional Recurrence After Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Adverse Impact of Multifocal Disease and Potential Implications of Dose Escal...
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803.
- Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid Tumors.
- The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of ColoRectal Adenoma.
- Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.
- C-reactive Protein and Risk of ColoRectal Adenoma According to Celecoxib Treatment.
- Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer--A Study of ...
- Documenting the Natural History of Patients With Resected Stage II AdenoCarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observ...
- Immunohistochemical and Molecular Analysis of Tyrosine Kinase Activity in Desmoid Tumors.
- VICTOR spoiled?
- Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic Intestinal inflammation in the min/+ mouse model of colon tumorigenesis.
- Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.
- Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated Intestinal fibrosis.
- Cytoreductive surgery in patients with metastatic gastroIntestinal stromal tumor treated with sunitinib malate.
- Molecular origins of cancer: Molecular basis of coloRectal cancer.
- The forest and the trees: pathways and proteins as coloRectal cancer biomarkers.
- Secondary sarcomas after radiotherapy for breast Cancer: sustained risk and poor survival.
- 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon Tumors.
- Cytochrome P450 2C9 variants influence response to celecoxib for prevention of coloRectal adenoma.
- Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon Cancer: Cancer and Leukemia ...
- p27Kip1 in stage III colon Cancer: implications for outcome following adjuvant chemotherapy in Cancer and leukemia group B protocol 89803.
- Prostaglandin inhibition and cardioVascular risk: maybe timing really is everything.
- Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid Cancer cells.
- Controversies in the surgical management of GIST in the era of imatinib.
- Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastroIntestinal st...
- A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
- Aberrant crypt foci in the adenoma prevention with celecoxib trial.
- LeiomyoSarcoma of the inferior vena cava: survival after aggressive management.
- Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice.
- The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic coloRectal cancer.
- Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor.
- Surgical management of advanced gastroIntestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
- Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility.
- Radioimmunotherapy for coloRectal cancer.
- Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse.
- Surgical prevention of Cancer.
- Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon Cancers.
- Apc deficiency is associated with increased Egfr activity in the Intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice.
- APC promoter hypermethylation contributes to the loss of APC expression in coloRectal cancers with allelic loss on 5q.
- Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal Cancer.
- Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic coloRectal cancers.
- Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of coloRectal cancer.
- The potential of non-steroidal anti-inflammatory drugs (NSAIDs) for coloRectal cancer prevention.
- ColoRectal cancer prevention studies: the importance of defining disease risk.
- Characterization of sporadic colon Cancer by patterns of genomic instability.
- Current management of metastatic gastroIntestinal stromal tumor: a case report.
- Adenomatous polyposis coli truncation alters cytoskeletal structure and microtubule stability in early Intestinal tumorigenesis.
- Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
- MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803...
Schools
University Of Utah School Of Medicine
Brigham and Women39s Hospital
Procedures Preformed
- Adrenalectomy
- Appendectomy, Open
- Biopsy of Breast
- Colectomy
- View All
Conditions Treated
- Abdominal Pain
- Anal and Rectal Cancer
- AnoRectal Abscess
- Atelectasis
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- Boston Magazine
- Meaningful Use Stage 1 Certification
- Fellow (FACS)
Education
-
Brigham and Women's Hospital -
University of Utah School of Medicine
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1528024270 |
| Last Name Of The Provider | BERTAGNOLLI |
| First Name Of The Provider | MONICA |
| View All |
Similar Doctors
|
|
Dr. Alex B. Haynes, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan Young, MDCM |
|
|
Tammy M. Holm |
|
|
Dr. Elisabeth Tracy, MD |
|
|
Dr. Patricia C. Chui, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul S. Russell, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sareh Parangi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michael Tarnoff, MD
This Doctor is OpenDoctor Recommended.
|